Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.76, for a total transaction of $447,600.00. Following the sale, the insider now owns 95,034 shares of the company’s stock, valued at approximately $4,253,721.84. This represents a 9.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.88, for a total transaction of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Price Performance

AKRO stock opened at $44.78 on Thursday. The company’s 50-day moving average price is $43.16 and its two-hundred day moving average price is $34.21. The firm has a market cap of $3.57 billion, a P/E ratio of -11.94 and a beta of -0.19. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). On average, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Canaccord Genuity Group upped their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Citigroup upped their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. UBS Group raised their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $76.29.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. abrdn plc boosted its stake in Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company’s stock valued at $7,505,000 after buying an additional 146,424 shares in the last quarter. FMR LLC lifted its holdings in shares of Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after acquiring an additional 26,691 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Akero Therapeutics in the 4th quarter valued at approximately $320,000. SG Americas Securities LLC grew its holdings in shares of Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares during the last quarter. Finally, Barclays PLC increased its position in Akero Therapeutics by 127.9% during the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock worth $3,662,000 after purchasing an additional 71,652 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.